Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
135M
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
69.8M
-
Shares change
-
+1.08M
-
Total reported value, excl. options
-
$276M
-
Value change
-
+$1.73M
-
Number of buys
-
42
-
Number of sells
-
-31
-
Price
-
$3.95
Significant Holders of Tango Therapeutics, Inc. - Common Stock (TNGX) as of Q1 2023
98 filings reported holding TNGX - Tango Therapeutics, Inc. - Common Stock as of Q1 2023.
Tango Therapeutics, Inc. - Common Stock (TNGX) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 69.8M shares
of 135M outstanding shares and own 51.87% of the company stock.
Largest 10 shareholders include TRV GP IV, LLC (19.4M shares), FMR LLC (9.51M shares), Boxer Capital, LLC (7.12M shares), Southpoint Capital Advisors LP (4.5M shares), EcoR1 Capital, LLC (4.2M shares), Cormorant Asset Management, LP (4.12M shares), BlackRock Inc. (3.54M shares), VANGUARD GROUP INC (2.75M shares), Bain Capital Life Sciences Investors, LLC (1.92M shares), and Avoro Capital Advisors LLC (1.64M shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.